ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0240

Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

Meeting: ACR Convergence 2024

Keywords: , , ,

Session Information

Date: Saturday, November 16, 2024

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence of cellular and humoral immunity following repeated SARS-CoV-2 vaccine doses and infection is important to evaluate the need for booster vaccine doses.

The objective of this study was to assess the cellular and humoral responses to monovalent 4th (original) and bivalent 5th (updated BA.1 or BA.4/5) SARS-CoV-2 vaccine doses and to COVID-19 following a 4th vaccine dose (hybrid immunity) in IMID patients on tumour necrosis factor inhibitors (TNFi). 

Methods: The ongoing observational Nor-vaC study includes patients with arthritis or inflammatory bowel disease receiving multiple SARS-CoV-2 vaccines.

The present analyses include patients using TNFi. The 4th dose group received four monovalent vaccine doses; the 4th dose hybrid group received four monovalent vaccine doses followed by COVID-19; the 5th dose hybrid group had COVID-19 between a 4th monovalent and a 5th bivalent vaccine dose.

Participants provided serum and peripheral blood mononuclear cells (PBMCs) 2-4 weeks after vaccines and COVID-19, and prior to a 5th dose (median 6 months (IQR 4-11 months) after COVID-19). CD4 and CD8 T cell responses to SARS-CoV-2 spike and IgG anti-spike antibodies were analysed. T cell responses were measured by flow cytometry (≥0.01% increase in responding CD4 or CD8 cells compared to unstimulated cells).

Results: Between December 17th 2021, and June 20th 2023, 382 IMID patients (86 rheumatoid arthritis, 66 psoriatic arthritis, 94 spondyloarthritis, 84 Crohn’s disease, 52 ulcerative colitis) on TNFi in mono- (61%) or combination therapy (39%) received a 4th monovalent and a 5th bivalent vaccine dose (82%), and 57 % had COVID-19 following a 4th vaccine dose, median age 57 (IQR 46–66), 201 female (53%). Overall, 69 patients provided PBMCs, and 382 patients provided serum samples. 

Infection induced no significant increase in spike-specific CD4 T cell responses in individuals who had already received a 4th dose (Table). CD4 T cell responses after hybrid immunity waned over the next 6 months, and a 5th vaccine dose restored CD4 T cell responses to the level seen 2-4 weeks after infection.

CD8 T cell responses following 4th vaccine dose remained stable after infection and also in the next 6 months (Figure). CD8 T cell responses to a 5th vaccine dose did not significantly differ from those post-infection or a 4th vaccine dose.

Patients with hybrid immunity had higher IgG anti-spike antibody levels than patients receiving only 4th dose. This humoral response had waned prior to, but increased following the 5th vaccine dose.

Conclusion: In IMID patients on TNFi who had undergone COVID-19 during the last six months,CD4 T cell and humoral responses waned over time following four vaccinations and infection, with responses restored by a vaccine booster.

However, CD8 T cell responses after four immunisations showed no significant benefit of further booster doses, suggesting established, long-lived cellular responses after four SARS-CoV-2 vaccine doses that could be clinically protective.  

Supporting image 1

Figure: CD4 and CD8 T cell responses, and anti-spike antibody levels, in the 4th dose group, the 4th dose hybrid group, and the 5th dose hybrid group before (pre-5th dose) and after vaccination (5th dose hybrid).

Supporting image 2

Table: Comparisons of CD4 and CD8 T cell responses, and anti-spike antibody levels between the 4th dose, the 4th dose hybrid (following COVID_19 after a 4th dose), and the 5th dose hybrid group before (pre-5th dose) and after vaccination (5th dose hybrid).

Disclosures: H. Ørbo: None; A. Wolf: None; T. Kasahara: None; K. Bjørlykke: Janssen-Cilag, 6; I. Jyssum: None; J. Sexton: None; A. Tveter: None; G. Solum: None; I. Kjønstad: None; I. Christensen: None; T. Kvien: AbbVie/Abbott, 1, 2, 5, Bristol-Myers Squibb(BMS), 5, Galapagos, 5, Gilead, 2, Grünenthal, 6, Janssen, 2, 6, Novartis, 2, 5, Pfizer, 2, 5, Sandoz, 2, 6, UCB, 2, 5; J. Jahnsen: AbbVie/Abbott, 1, 3, 6, Bristol-Myers Squibb(BMS), 1, 6, Galapagos, 1, 6, Gilead, 1, 6, Janssen, 1, 6, Pfizer, 1, 2, 5, Roche, 1, 6, Sandoz, 1, 6, Takeda, 1, 6; E. Haavardsholm: AbbVie/Abbott, 2, Celgene, 2, Eli Lilly, 2, Gilead, 2, Janssen, 2, Pfizer, 2, UCB, 2; L. Munthe: Incyte, 6, Janssen, 6; S. Provan: Boehringer-Ingelheim, 2; J. Vaage: None; K. Jørgensen: Bristol-Myers Squibb(BMS), 6, Roche, 6; G. Grødeland: AstraZeneca, 1, Bayer, 6, GlaxoSmithKlein(GSK), 6, Janssen, 1, Moderna, 1, Pfizer, 6, Sanofi, 6, Seqirus, 1, ThermoFisher, 6; S. Mjaaland: None; S. Syversen: AstraZeneca, 1; G. Goll: AbbVie/Abbott, 1, 6, Galapagos, 1, 6, Novartis, 1, Pfizer, 1, 6, UCB, 1, 6.

To cite this abstract in AMA style:

Ørbo H, Wolf A, Kasahara T, Bjørlykke K, Jyssum I, Sexton J, Tveter A, Solum G, Kjønstad I, Christensen I, Kvien T, Jahnsen J, Haavardsholm E, Munthe L, Provan S, Vaage J, Jørgensen K, Grødeland G, Mjaaland S, Syversen S, Goll G. Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cellular-and-humoral-responses-following-a-fifth-updated-sars-cov-2-vaccine-dose-and-hybrid-immunity-in-patients-on-tnf-inhibitors-a-prospective-cohort-study/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cellular-and-humoral-responses-following-a-fifth-updated-sars-cov-2-vaccine-dose-and-hybrid-immunity-in-patients-on-tnf-inhibitors-a-prospective-cohort-study/